img-desktop-purple-hero-background

Rigorously Evaluated

Rigorously Evaluated

img-mobile-purple-hero-background

It’s important that HIV care is individualized and representative of a diverse patient population

FDA guidance on HIV clinical trial design1
  • Trials should include adequate US patient representation, which includes an adequate representation of males and females, races, ages, and weights
  • The inclusion of a diverse patient population early in drug development can help identify potential efficacy or safety issues across a wide range of patients

A rigorously evaluated regimen with data from diverse patient demographics may help inform your treatment plan for specific patients you may see in your clinic. Consider prioritizing patient-centricity and delivering HIV care with sensitivity and persistence.2

Understanding stigma is a critical part of HIV treatment

Addressing the issues, taking on the challenges
Scroll down to learn more

People featured are compensated by Gilead.

Effects of HIV-related stigma

According to a 2024 online survey* of 2,511 adults in the US, more than 8 in 10 believe there is still a stigma around HIV.3 For people with HIV, this stigma may lead to:
  • Mental health issues4
  • Racial/ethnic disparities in care5
  • Underrepresentation in clinical trials6
  • Medical mistrust6

*The State of HIV Stigma Study was conducted in January 2024 via online survey of 2,511 adults aged ≥18 years in the United States. The sample was sourced and aggregated by Cint.3

FDA, US Food and Drug Administration.

References:
  1. US Food & Drug Administration. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Published November 2015. Accessed December 5, 2024. https://www.fda.gov/media/86284/download
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated September 12, 2024. Accessed January 8, 2025. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
  3. GLAAD. 2024 State of HIV Stigma Report. Published 2024. Accessed February 25, 2025. https://assets.glaad.org/m/7f1927b6af934747/original/2024-State-of-HIV-Stigma-Study.pdf
  4. Turan B, Budhwani H, Fazeli PL, et al. How does stigma affect people living with HIV? The mediating roles of internalized and anticipated HIV stigma in the effects of perceived community stigma on health and psychosocial outcomes. AIDS Behav. 2017;21(1):283-291.
  5. American Psychological Association. HIV/AIDS and socioeconomic status. Updated April 2022. Accessed December 10, 2024. https://www.apa.org/pi/ses/resources/publications/hiv-aids
  6. Bass SB, D'Avanzo P, Alhajji M, et al. Exploring the engagement of racial and ethnic minorities in HIV treatment and vaccine clinical trials: a scoping review of literature and implications for future research. AIDS Patient Care and STDs. 2020;34(9):399-416.